Protocol Ledger

NCT04498117 · Phase III · ACTIVE NOT RECRUITING

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Interventional Phase III clinical trial protocol NCT04498117 sponsored by CanariaBio in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-25 Enrollment: 615 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04498117
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)615 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04498117
Protocol FieldVerified Registry Value
NCT IdentifierNCT04498117
Consolidated Lead SponsorCanariaBio
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment615 participants (ACTUAL)
Registered Start Date2020-08-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04498117
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
Kaiser Permanente Los Angeles Medical CenterLos Angeles, CAOpen Hospital Dossier ->
UC Davis Comprehensive Cancer CenterSacramento, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI